Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the ocular hypertension treatment study

James D Brandt, Julia A. Beiser, Mae O. Gordon, Michael A. Kass

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

To determine whether central corneal thickness (CCT) correlates with measured intraocular pressure (IOP) response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study (OHTS). Prospective randomized clinical trial. Intraocular pressure measurements were performed by Goldmann applanation tonometry. Central corneal thickness was measured by ultrasonic pachymetry. The following indicators of IOP response to topical ocular hypotensive medication were examined: (1) IOP after an initial four- to six-week one-eyed therapeutic trial of a nonselective β-blocker (N = 549) or a prostaglandin analog (N = 201); (2) the mean IOP response during 12 to 60 months of follow-up among medication participants (N = 689); (3) the percentage of follow-up visits at which both eyes met the treatment goal; (4). the total number of different medications prescribed to reach treatment goal; and (5) the total number of different medications prescribed multiplied by the number of months each medication was prescribed. Central corneal thickness was inversely related to the IOP response after the initial one-eyed therapeutic trial and during 12 to 60 months of follow-up (P < .05). Mean CCT was not correlated with the number of different medications prescribed during follow-up, the total medication-months, or the percentage of visits at which IOP target was met. Individuals with thicker corneas had smaller measured IOP responses to ocular hypotensive medication than those with normal or thin corneas. We believe that CCT measurements may be useful in patient management and in interpreting clinical trials of ocular hypotensive medication.

Original languageEnglish (US)
Pages (from-to)717-722
Number of pages6
JournalAmerican Journal of Ophthalmology
Volume138
Issue number5
DOIs
StatePublished - Nov 2004

Fingerprint

Ocular Hypertension
Intraocular Pressure
Cornea
Corneal Pachymetry
Synthetic Prostaglandins
Therapeutics
Manometry
Ultrasonics
Randomized Controlled Trials
Clinical Trials

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the ocular hypertension treatment study. / Brandt, James D; Beiser, Julia A.; Gordon, Mae O.; Kass, Michael A.

In: American Journal of Ophthalmology, Vol. 138, No. 5, 11.2004, p. 717-722.

Research output: Contribution to journalArticle

@article{a0e2e72660ef4e06b92091a4b82a661a,
title = "Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the ocular hypertension treatment study",
abstract = "To determine whether central corneal thickness (CCT) correlates with measured intraocular pressure (IOP) response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study (OHTS). Prospective randomized clinical trial. Intraocular pressure measurements were performed by Goldmann applanation tonometry. Central corneal thickness was measured by ultrasonic pachymetry. The following indicators of IOP response to topical ocular hypotensive medication were examined: (1) IOP after an initial four- to six-week one-eyed therapeutic trial of a nonselective β-blocker (N = 549) or a prostaglandin analog (N = 201); (2) the mean IOP response during 12 to 60 months of follow-up among medication participants (N = 689); (3) the percentage of follow-up visits at which both eyes met the treatment goal; (4). the total number of different medications prescribed to reach treatment goal; and (5) the total number of different medications prescribed multiplied by the number of months each medication was prescribed. Central corneal thickness was inversely related to the IOP response after the initial one-eyed therapeutic trial and during 12 to 60 months of follow-up (P < .05). Mean CCT was not correlated with the number of different medications prescribed during follow-up, the total medication-months, or the percentage of visits at which IOP target was met. Individuals with thicker corneas had smaller measured IOP responses to ocular hypotensive medication than those with normal or thin corneas. We believe that CCT measurements may be useful in patient management and in interpreting clinical trials of ocular hypotensive medication.",
author = "Brandt, {James D} and Beiser, {Julia A.} and Gordon, {Mae O.} and Kass, {Michael A.}",
year = "2004",
month = "11",
doi = "10.1016/j.ajo.2004.07.036",
language = "English (US)",
volume = "138",
pages = "717--722",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the ocular hypertension treatment study

AU - Brandt, James D

AU - Beiser, Julia A.

AU - Gordon, Mae O.

AU - Kass, Michael A.

PY - 2004/11

Y1 - 2004/11

N2 - To determine whether central corneal thickness (CCT) correlates with measured intraocular pressure (IOP) response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study (OHTS). Prospective randomized clinical trial. Intraocular pressure measurements were performed by Goldmann applanation tonometry. Central corneal thickness was measured by ultrasonic pachymetry. The following indicators of IOP response to topical ocular hypotensive medication were examined: (1) IOP after an initial four- to six-week one-eyed therapeutic trial of a nonselective β-blocker (N = 549) or a prostaglandin analog (N = 201); (2) the mean IOP response during 12 to 60 months of follow-up among medication participants (N = 689); (3) the percentage of follow-up visits at which both eyes met the treatment goal; (4). the total number of different medications prescribed to reach treatment goal; and (5) the total number of different medications prescribed multiplied by the number of months each medication was prescribed. Central corneal thickness was inversely related to the IOP response after the initial one-eyed therapeutic trial and during 12 to 60 months of follow-up (P < .05). Mean CCT was not correlated with the number of different medications prescribed during follow-up, the total medication-months, or the percentage of visits at which IOP target was met. Individuals with thicker corneas had smaller measured IOP responses to ocular hypotensive medication than those with normal or thin corneas. We believe that CCT measurements may be useful in patient management and in interpreting clinical trials of ocular hypotensive medication.

AB - To determine whether central corneal thickness (CCT) correlates with measured intraocular pressure (IOP) response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study (OHTS). Prospective randomized clinical trial. Intraocular pressure measurements were performed by Goldmann applanation tonometry. Central corneal thickness was measured by ultrasonic pachymetry. The following indicators of IOP response to topical ocular hypotensive medication were examined: (1) IOP after an initial four- to six-week one-eyed therapeutic trial of a nonselective β-blocker (N = 549) or a prostaglandin analog (N = 201); (2) the mean IOP response during 12 to 60 months of follow-up among medication participants (N = 689); (3) the percentage of follow-up visits at which both eyes met the treatment goal; (4). the total number of different medications prescribed to reach treatment goal; and (5) the total number of different medications prescribed multiplied by the number of months each medication was prescribed. Central corneal thickness was inversely related to the IOP response after the initial one-eyed therapeutic trial and during 12 to 60 months of follow-up (P < .05). Mean CCT was not correlated with the number of different medications prescribed during follow-up, the total medication-months, or the percentage of visits at which IOP target was met. Individuals with thicker corneas had smaller measured IOP responses to ocular hypotensive medication than those with normal or thin corneas. We believe that CCT measurements may be useful in patient management and in interpreting clinical trials of ocular hypotensive medication.

UR - http://www.scopus.com/inward/record.url?scp=7544224832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7544224832&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2004.07.036

DO - 10.1016/j.ajo.2004.07.036

M3 - Article

C2 - 15531304

AN - SCOPUS:7544224832

VL - 138

SP - 717

EP - 722

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 5

ER -